Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Expression Level
100%
Human Cancer
100%
P27Kip1
100%
Biomarkers of Response
100%
Rapalogs
100%
P27 Expression
18%
BT-474 Cells
18%
MCF-7
9%
Gene Expression
9%
Phosphorylation
9%
Antitumor Activity
9%
Patient Selection
9%
Basal Level
9%
MDA-MB-231
9%
Human Tumors
9%
Cancer Cells
9%
Temsirolimus
9%
Prognostic Biomarker
9%
Small Interfering RNA (siRNA)
9%
T47D
9%
Gene Expression Profile
9%
Clinical Trials
9%
Objective Response Rate
9%
Xenograft
9%
Mechanistic Studies
9%
Cellular Level
9%
Rapamycin
9%
Response Predictors
9%
Everolimus
9%
Clinical Validation
9%
Rapamycin Analogs
9%
MDA-MB-468
9%
Anticancer Activity
9%
Pearson Correlation Coefficient
9%
G1-S Transition
9%
MDA-MB-435 Cells
9%
Gene Probes
9%
NCI-60 Cell Lines
9%
MCF-7 Cancer Cells
9%
P27 Gene
9%
Advanced Renal Cell Carcinoma (aRCC)
9%
Immunology and Microbiology
Gene Expression
100%
Antineoplastic Activity
100%
Sirolimus
100%
Cell Line
50%
Cancer Cell
50%
Xenograft
50%
Downregulation
50%
Everolimus
50%
Gene Probe
50%
Temsirolimus
50%
In Vitro
50%
phosphorylation
50%
Biochemistry, Genetics and Molecular Biology
Expression Level
100%
Gene Expression
66%
Antineoplastic Activity
66%
Cancer Cell
33%
Clinical Trial
33%
Downregulation
33%
G1/S Transition
33%
MDA-MB-468
33%
Gene Probe
33%
Small Interfering RNA
33%
phosphorylation
33%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Biological Marker
100%
Rapamycin
66%
Neoplasm
33%
Clinical Trial
33%
Breast Cancer
33%
Temsirolimus
33%
Small Interfering RNA
33%
Everolimus
33%
Kidney Cancer
33%